Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 297

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

Open access
Murai, Junko, Feng, Ying, Yu, Guoying K., Ru, Yuanbin, Tang, Sai-Wen, Shen, Yuqiao, Pommier, Yves · 2016 · Oncotarget

Abstract

// Junko Murai 1 , Ying Feng 2 , Guoying K. Yu 2 , Yuanbin Ru 2 , Sai-Wen Tang 1,3 , Yuqiao Shen 2 and Yves Pommier 1 1 Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 2 BioMarin Pharmaceutical Inc., Novato, CA, USA 3 Current affiliation: Division of Blood and Marrow Transplantation, Department of Medicine, Stranford University School of Medicine, Stanford, CA, USA Correspondence to: Yves Pommier, email: // Keywords : PARP-trapping, ATR, PARP inhibitor, BRCA, homologous recombination Received : August 25, 2016 Accepted : August 26, 2016 Published : September 27, 2016 Abstract Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits remarkable selectivity among the NCI-60 cancer cell lines beyond BRCA inactivation. Our genomic analyses reveal high correlation between response to talazoparib and Schlafen 11 ( SLFN11 ) expression. Causality was established in four isogenic SLFN11 -positive and -negative cell lines and extended to olaparib. Response to the talazoparib-temozolomide combination was also driven by SLFN11 and validated in 36 small cell lung cancer cell lines, and in xenograft models. Resistance in SLFN11 -deficient cells was caused neither by impaired drug penetration nor by activation of homologous recombination. Rather, SLFN11 induced irreversible and lethal replication inhibition, which was independent of ATR-mediated S-phase checkpoint. The resistance to PARPIs by SLFN11 inactivation was overcome by ATR inhibition, mechanistically because SLFN11 -deficient cells solely rely on ATR activation for their survival under PARPI treatment. Our study reveals that SLFN11 inactivation, which is common (~45%) in cancer cells, is a novel and dominant resistance determinant to PARPIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12266

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

Metadata

Authors
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y.
Venue
Oncotarget
Published
2016-09-27
Volume
7
Issue
47
Pages
76534-76550
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2528953057
Cited by
297
References
58
FWCI
10.66
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.